Clearmind Medicine Inc
NASDAQ:CMND
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1.81
59.6
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Clearmind Medicine Inc
Clearmind Medicine, Inc. operates as a mineral resource company, which acquires, explores, develops, and operates mineral resource assets in Canada. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2018-05-15. The firm is focused on the discovery and development of novel psychedelic derived therapeutics to solve health problems including alcohol use disorder. The firm is engaged in the research and development of compounds derived from psychedelics and commercializes them as regulated medicines, foods, or supplements. The firm's portfolio consists of patent families such as binge behavior regulators and alcoholic beverage substitutes.
Clearmind Medicine, Inc. operates as a mineral resource company, which acquires, explores, develops, and operates mineral resource assets in Canada. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2018-05-15. The firm is focused on the discovery and development of novel psychedelic derived therapeutics to solve health problems including alcohol use disorder. The firm is engaged in the research and development of compounds derived from psychedelics and commercializes them as regulated medicines, foods, or supplements. The firm's portfolio consists of patent families such as binge behavior regulators and alcoholic beverage substitutes.
